This site uses cookies.
Some of these cookies are essential to the operation of the site,
while others help to improve your experience by providing insights into how the site is being used.
For more information, please see the ProZ.com privacy policy.
Freelance translator and/or interpreter, Verified site user
Data security
This person has a SecurePRO™ card. Because this person is not a ProZ.com Plus subscriber, to view his or her SecurePRO™ card you must be a ProZ.com Business member or Plus subscriber.
Affiliations
This person is not affiliated with any business or Blue Board record at ProZ.com.
English to Portuguese: Sample Medical Translation General field: Medical
Source text - English Chimeric antigen receptor (CAR) T-cell therapy has fundamentally changed the therapeutic landscape for haematological malignancies. CAR T-cell therapy involves the collection of a patient’s T cells, ex-vivo genetic modification of the cells to encode a synthetic receptor that binds a specific tumour antigen, and then re-infusion of these cells back into the patient. The clinical success of CAR T-cell therapy in blood cancers has generated enthusiasm for testing the technology in solid tumours. However, the biology of solid tumours is more complex than that of haematological malignancies. Unfortunately, CAR T-cell therapy for solid tumours suffered a setback on June 2, 2021, when Tmunity Therapeutics stopped its phase 1 clinical trial in men with prostate cancer because two patients died from immune effector cell-associated neurotoxicity syndrome (ICANS)
Translation - Portuguese O uso da terapia de Receptores de Antígeno Quimérico (CAR) em células T alterou significativamente o cenário terapêutico para doenças hematológicas malignantes. A terapia CAR em células T, envolve a coleta das células T do paciente, a modificação celular genética do "ex vivo" para decodificar um receptor sintético vinculado a um antígeno tumoral específico, e em seguida, ocorre a re-infusão celular no paciente. O sucesso clínico da terapia CAR em células T em cânceres hematológicos tem gerado entusiasmo para que essa tecnologia seja testada em tumores sólidos. Contudo, a biologia celular de tumores sólidos é mais complexa que a de malignidades hematológicas. Infelizmente, a terapia CAR em células T em tumores sólidos sofreu um retrocesso em 2 de Junho de 2021, quando a empresa bioterapêutica Tmunity Therapeutics interrompeu a fase 1 de seu ensaio clínico em homens com câncer de próstata porque 2 (dois) pacientes morreram de Síndrome de Neurotoxicidade Associada à Células Efetoras Imunes (ICANS).
More
Less
Experience
Years of experience: 10. Registered at ProZ.com: Oct 2008.
Certified Portuguese
Medical Interpreter working for over 7 years as a remote interpreter (OPI/VRI).
Recently started working as a Translator specializing in the medical field.
Language pairs: PTBr to and from EN, and SPA to PTBr. Organized and dependable
candidate, successful at managing multiple priorities with a positive attitude.
Willingness to take on added responsibilities to meet team goals. Friendly
professional available for weekend, evening, and holiday shifts. Considered hardworking,
punctual and driven. Focused Translator with highly developed understanding of
Brazilian Portuguese language and culture. Skilled in quickly and accurately
translating written documents.
Expertise 
